Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b
Therapeutic Advances in Hematology
Published online on March 30, 2026
Abstract
Therapeutic Advances in Hematology, Volume 17, January-December 2026.
Background:Polycythemia vera (PV) is a myeloproliferative neoplasm driven byJAK2V617F mutations. Ropeginterferon alfa-2b effectively reduces both hematologic parameters andJAK2allele burden, but molecular monitoring is not always readily available....
Background:Polycythemia vera (PV) is a myeloproliferative neoplasm driven byJAK2V617F mutations. Ropeginterferon alfa-2b effectively reduces both hematologic parameters andJAK2allele burden, but molecular monitoring is not always readily available....